Related Experiment Video
Updated: Sep 11, 2025
Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021
Antibacterial Activity of MC-170, a 2,2-Disubstituted Indole-3-one Derivative, Against Staphylococcus aureus via
Yumiao Zhao1,2, Xuelu Tian3, Jie Bao4
1Central Laboratory, Jining No.1 People's Hospital, Jining, China.
Abstract:
Staphylococcus aureus, a major human pathogen, poses a significant threat in both healthcare settings and the community. Developing novel inhibitors against S. aureus and elucidating their antibacterial mechanisms represents a highly promising strategy for combating S. aureus infections. In this study, we investigated the molecular mechanism underlying the antibacterial activity of MC170, a 2,2-disubstituted indole-3-one derivative exhibiting potent and selective activity against S. aureus, including methicillin-resistant S. aureus (MRSA). MC170 demonstrated strong inhibitory effects, with minimum inhibitory concentrations of 1 µg/mL against S. aureus and 2 µg/mL against MRSA. Growth curve measurements and time-kill curves were employed to analyze the growth patterns of S. aureus exposed to MC170. Transcriptome analysis was performed on S. aureus to further elucidate the mechanism by which MC-170 inhibits the growth of S. aureus. Transcriptome analysis revealed that MC170 significantly disrupted glycolysis/gluconeogenesis and carbon metabolism. These pathways are critical for generating essential precursors required for bacterial membrane phospholipid biosynthesis. Notably, exogenous phosphatidylglycerol (PG) significantly attenuated the antibacterial activity of MC170. These findings collectively suggest that MC170 exerts its antibacterial effects through inhibition of PG metabolism. Elucidating the antibacterial mechanism of MC170 could provide a foundation for developing novel strategies to combat antimicrobial resistance.
Insights
A novel compound, MC170, effectively inhibits Staphylococcus aureus growth by disrupting essential metabolic pathways. This compound targets phosphatidylglycerol metabolism, offering a new strategy against antibiotic-resistant bacteria like MRSA.
Area of Science:
- Microbiology
- Molecular Biology
- Drug Discovery
Background:
- Staphylococcus aureus is a significant human pathogen causing infections in healthcare and community settings.
- Developing novel antibacterial agents and understanding their mechanisms is crucial for combating S. aureus and antimicrobial resistance.
Purpose of the Study:
- To investigate the molecular mechanism of action of MC170, a potent inhibitor of S. aureus.
- To elucidate how MC170 disrupts bacterial growth and identify its specific molecular targets.
Main Methods:
- Minimum inhibitory concentration (MIC) determination for S. aureus and MRSA.
- Growth curve and time-kill assays to assess bacterial growth inhibition.
- Transcriptome analysis to identify disrupted cellular pathways.
- Assessment of MC170 activity in the presence of exogenous phosphatidylglycerol (PG).
Main Results:
- MC170 exhibited potent activity against S. aureus (MIC = 1 µg/mL) and MRSA (MIC = 2 µg/mL).
- Transcriptome analysis revealed MC170 disrupts glycolysis/gluconeogenesis and carbon metabolism, essential for phospholipid biosynthesis.
- Exogenous PG significantly reduced MC170's antibacterial effect, indicating PG metabolism is involved.
Conclusions:
- MC170 exerts its antibacterial effect by inhibiting phosphatidylglycerol metabolism in S. aureus.
- Understanding MC170's mechanism provides a basis for developing new anti-S. aureus strategies to combat antimicrobial resistance.
